HK1200857A1 - Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists pd-1 vegf - Google Patents
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists pd-1 vegfInfo
- Publication number
- HK1200857A1 HK1200857A1 HK15101499.7A HK15101499A HK1200857A1 HK 1200857 A1 HK1200857 A1 HK 1200857A1 HK 15101499 A HK15101499 A HK 15101499A HK 1200857 A1 HK1200857 A1 HK 1200857A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vegf
- antagonists
- methods
- treating cancer
- axis binding
- Prior art date
Links
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 2
- 101150030763 Vegfa gene Proteins 0.000 title 2
- 239000005557 antagonist Substances 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261653861P | 2012-05-31 | 2012-05-31 | |
PCT/US2013/043452 WO2013181452A1 (en) | 2012-05-31 | 2013-05-30 | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1200857A1 true HK1200857A1 (en) | 2015-08-14 |
Family
ID=48626639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15101499.7A HK1200857A1 (en) | 2012-05-31 | 2015-02-11 | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists pd-1 vegf |
Country Status (19)
Country | Link |
---|---|
US (3) | US9895441B2 (ru) |
EP (2) | EP3556776A1 (ru) |
JP (3) | JP6312659B2 (ru) |
KR (2) | KR20200079568A (ru) |
CN (1) | CN104271601B (ru) |
AR (1) | AR091220A1 (ru) |
AU (3) | AU2013267267B2 (ru) |
BR (1) | BR112014029887A8 (ru) |
CA (1) | CA2874144C (ru) |
ES (1) | ES2742379T3 (ru) |
HK (1) | HK1200857A1 (ru) |
IL (2) | IL235779B (ru) |
MX (2) | MX363872B (ru) |
MY (1) | MY186099A (ru) |
PL (1) | PL2855528T3 (ru) |
RU (1) | RU2689760C2 (ru) |
SG (2) | SG10201603055WA (ru) |
WO (1) | WO2013181452A1 (ru) |
ZA (1) | ZA201408852B (ru) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
EP3929216A1 (en) | 2008-12-09 | 2021-12-29 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
EP3495387B1 (en) | 2012-07-13 | 2021-09-01 | Roche Glycart AG | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
ES2707323T3 (es) | 2012-12-07 | 2019-04-03 | Chemocentryx Inc | Diazol lactamas |
CN105339389B (zh) | 2013-05-02 | 2021-04-27 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
SI3081576T1 (sl) | 2013-12-12 | 2019-12-31 | Shanghai Hengrui Pharmaceutical Co., Ltd., | Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
MX2016010082A (es) | 2014-02-04 | 2016-10-07 | Pfizer | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1) y un inhibidor del receptor del factor de crecimiento endotelial vascular (vegfr) para tratar cancer. |
RS62038B1 (sr) | 2014-02-10 | 2021-07-30 | Merck Patent Gmbh | Ciljana tgf beta inhibicija |
EP3149043A1 (en) * | 2014-05-29 | 2017-04-05 | Medimmune Limited | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
SG11201700496WA (en) | 2014-07-22 | 2017-02-27 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
CN110964108B (zh) | 2014-08-05 | 2023-07-07 | 中美冠科生物技术(太仓)有限公司 | 抗pd-l1抗体 |
WO2016025647A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
CA2957717C (en) | 2014-08-12 | 2021-10-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein |
US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
CN107428825A (zh) * | 2014-10-10 | 2017-12-01 | 创祐生技股份有限公司 | 治疗及/或预防肿瘤生长、侵袭及/或转移的方法 |
TN2017000129A1 (en) | 2014-10-14 | 2018-10-19 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-l1 and uses thereof |
US20160158360A1 (en) * | 2014-12-05 | 2016-06-09 | Genentech, Inc. | Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists |
BR112017018234A2 (pt) | 2015-02-26 | 2018-04-17 | Merck Patent Gmbh | inibidores de pd-1 / pd-l1 para o tratamento de câncer |
MA42971A (fr) * | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
EP3286217A1 (en) * | 2015-04-23 | 2018-02-28 | F. Hoffmann-La Roche AG | Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death ligand 1 |
KR20180014009A (ko) * | 2015-05-29 | 2018-02-07 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합 |
CA2985818A1 (en) * | 2015-05-31 | 2016-12-08 | Curegenix Corporation | Combination compositions comprising an antagonist of porcupine and a pd-l/pd-1 axis antagonist for immunotherapy |
JP6865177B2 (ja) * | 2015-06-11 | 2021-04-28 | バイオノミクス リミテッド | 医薬組み合わせおよびその使用 |
IL256245B (en) | 2015-06-16 | 2022-09-01 | Merck Patent Gmbh | Treatments that combine a pd-l1 antagonist |
KR20180029079A (ko) | 2015-07-31 | 2018-03-19 | 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. | 암에 대한 면역 체크포인트 억제제와의 조합 요법에서의 조혈 줄기 세포 |
AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
BR112018005862A2 (pt) * | 2015-09-25 | 2018-10-16 | Genentech, Inc. | anticorpos, anticorpos isolados, polinucleotídeo, vetor, célula hospedeira, método de produção do anticorpo, imunoconjugado, composição, usos dos anticorpos, métodos para tratar ou retardar a progressão de um câncer e de uma doença e para aumentar, potencializar ou estimular uma resposta ou função imune e kit |
JP7033788B2 (ja) | 2015-10-09 | 2022-03-11 | グローバル バイオファーマ インコーポレイテッド | 組み合わせ医薬 |
GB201522311D0 (en) | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
GB201522309D0 (en) | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
CA3006529A1 (en) | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
KR102281961B1 (ko) * | 2016-01-08 | 2021-07-26 | 다이호야쿠힌고교 가부시키가이샤 | 면역 조절제를 함유하는 항종양제 및 항종양 효과 증강제 |
JP2019506863A (ja) * | 2016-02-02 | 2019-03-14 | カドモン コーポレイション,リミティド ライアビリティ カンパニー | Pd−l1及びkdrに対する二重結合タンパク質 |
CN107126563B (zh) * | 2016-02-26 | 2021-09-10 | 博生吉医药科技(苏州)有限公司 | 含低剂量阻断vegf信号通路的抗体的组合物及其用途 |
EP3439653B1 (en) | 2016-04-07 | 2021-01-20 | ChemoCentryx, Inc. | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
CA3019921A1 (en) * | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
EP3482205A1 (en) | 2016-07-08 | 2019-05-15 | H. Hoffnabb-La Roche Ag | Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment |
CA3031168A1 (en) * | 2016-08-12 | 2018-02-15 | Merck Patent Gmbh | Combination therapy for cancer |
MX2019001635A (es) * | 2016-08-12 | 2019-06-10 | Genentech Inc | Terapia de combinacion con un inhibidor de mek, un inhibidor del eje de pd-1, y un inhibidor de vegf. |
WO2018065938A1 (en) | 2016-10-06 | 2018-04-12 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
KR20190065183A (ko) * | 2016-10-15 | 2019-06-11 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | Pd-1 항체 |
EP3666794A1 (en) | 2016-11-01 | 2020-06-17 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
EP3551663A1 (en) * | 2016-12-12 | 2019-10-16 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens |
JP7110206B6 (ja) | 2017-01-09 | 2022-08-25 | テサロ, インコーポレイテッド | 抗pd-1抗体を用いてがんを処置する方法 |
US10350266B2 (en) | 2017-01-10 | 2019-07-16 | Nodus Therapeutics, Inc. | Method of treating cancer with a multiple integrin binding Fc fusion protein |
JP2020505438A (ja) | 2017-01-10 | 2020-02-20 | ノダス・セラピューティクスNodus Therapeutics | インテグリン結合性ポリペプチド−Fc融合タンパク質および免疫調節物質を用いる併用がん治療法 |
WO2018160841A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
JP2020516253A (ja) * | 2017-04-14 | 2020-06-11 | ジェネンテック, インコーポレイテッド | がんのための診断及び治療方法 |
WO2018217688A1 (en) * | 2017-05-22 | 2018-11-29 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for inhibition of mica/b shedding |
WO2018223923A1 (zh) * | 2017-06-05 | 2018-12-13 | 江苏恒瑞医药股份有限公司 | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 |
WO2019051246A1 (en) * | 2017-09-08 | 2019-03-14 | Phosplatin Therapeutics Llc | PHOSPHAPLATINE COMPOUNDS AS IMMUNOMODULATORS AND THERAPEUTIC USES THEREOF |
IL273188B2 (en) | 2017-09-25 | 2023-03-01 | Chemocentryx Inc | Treatment with a combination of chemokine receptor 2 (ccr2) inhibitors and a pd-1/pd-l1 inhibitor |
CN109575140B (zh) * | 2017-09-29 | 2021-02-23 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
MA50423A (fr) | 2018-01-08 | 2020-08-26 | Chemocentryx Inc | Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2 |
US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
RU2756899C1 (ru) | 2018-02-28 | 2021-10-06 | ЭйПи БАЙОСАЙЕНСИЗ, ИНК. | Бифункциональные белки, комбинирующие блокаду контрольной точки, для таргетной терапии |
GB201803745D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
US20210253614A1 (en) | 2018-05-31 | 2021-08-19 | Peloton Therapeutics, Inc. | Compositions and methods for inhibiting cd73 |
CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
CA3116324A1 (en) | 2018-10-18 | 2020-04-23 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
CN113038939A (zh) | 2018-11-14 | 2021-06-25 | 瑞泽恩制药公司 | 损害内施用pd-1抑制剂用于治疗皮肤癌 |
US10952996B2 (en) | 2018-12-11 | 2021-03-23 | Theravance Biopharma R&D Ip, Llc | ALK5 inhibitors |
CN111378044B (zh) * | 2018-12-28 | 2022-07-15 | 长春金赛药业有限责任公司 | 抗体融合蛋白、制备方法及其应用 |
US20220259313A1 (en) | 2019-02-28 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Administration of a pd-1 inhibitor for for treating skin cancer |
EP3935085A1 (en) | 2019-03-06 | 2022-01-12 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
GB201914747D0 (en) * | 2019-10-11 | 2019-11-27 | Ultrahuman Eight Ltd | PD1 and vegfr2 dual-binding agents |
EP4061809A1 (en) | 2019-11-22 | 2022-09-28 | Theravance Biopharma R&D IP, LLC | Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors |
CN113214400B (zh) * | 2020-01-21 | 2022-11-08 | 甫康(上海)健康科技有限责任公司 | 一种双特异性抗pd-l1/vegf抗体及其用途 |
US11673879B2 (en) | 2020-03-31 | 2023-06-13 | Theravance Biopharma R&D Ip, Llc | Substituted pyrimidines and methods of use |
TW202210098A (zh) | 2020-05-26 | 2022-03-16 | 美商再生元醫藥公司 | 通過投予pd-1抑制劑治療子宮頸癌的方法 |
JP2023530275A (ja) | 2020-06-10 | 2023-07-14 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Alk5阻害剤として有用なナフチリジン誘導体 |
CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
EP4204592A1 (en) | 2020-08-26 | 2023-07-05 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer by administering a pd-1 inhibitor |
IL300975A (en) | 2020-09-03 | 2023-04-01 | Regeneron Pharma | Methods for treating cancer pain by administering a PD-1 inhibitor |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
EP4313123A1 (en) | 2021-03-23 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor |
TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
WO2022251359A1 (en) | 2021-05-26 | 2022-12-01 | Theravance Biopharma R&D Ip, Llc | Bicyclic inhibitors of alk5 and methods of use |
EP4353265A1 (en) * | 2021-06-10 | 2024-04-17 | ONO Pharmaceutical Co., Ltd. | Method for treating cancer through combination of cd47 inhibitor, immune checkpoint inhibitor, and standard therapy |
IL309831A (en) | 2021-07-13 | 2024-02-01 | BioNTech SE | Multispecific binding agents against CD40 and CD137 in combined cancer therapy |
CA3225932A1 (en) | 2021-07-19 | 2023-01-26 | Regeneron Pharmaceuticals, Inc. | Combination of checkpoint inhibitors and an oncolytic virus for treating cancer |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023159102A1 (en) | 2022-02-17 | 2023-08-24 | Regeneron Pharmaceuticals, Inc. | Combinations of checkpoint inhibitors and oncolytic virus for treating cancer |
WO2024115725A1 (en) | 2022-12-01 | 2024-06-06 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0558671B1 (en) | 1990-11-21 | 1999-01-27 | Iterex Pharmaceuticals Ltd. Partnership | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
DK1167384T3 (da) | 1992-10-28 | 2007-04-10 | Genentech Inc | Vaskular endotheliel cellevækstfaktor antagonister |
US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
DK0942968T3 (da) | 1996-12-03 | 2008-06-23 | Amgen Fremont Inc | Fuldt humane antistoffer, der binder EGFR |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
DK0971959T3 (da) | 1997-04-07 | 2006-05-15 | Genentech Inc | Humaniserede antistoffer og fremgangsmåder til dannelse af humaniserede antistoffer |
DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1556684A4 (en) | 2002-11-01 | 2008-01-23 | Univ Colorado Regents | QUANTITATIVE ANALYSIS OF PROTEIN ISOFORMS USING FLIGHT TIME MASS SPECTROMETRY BY MATRIX ASSISTED LASER DESORPTION / IONIZATION |
KR20160114727A (ko) | 2003-05-30 | 2016-10-05 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
WO2006121169A1 (en) * | 2005-05-09 | 2006-11-16 | Kabushiki Kaisha Toshiba | Liquid fuel, fuel cartridge and fuel cell |
PT2161336E (pt) | 2005-05-09 | 2013-10-03 | Ono Pharmaceutical Co | Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿ |
KR101607288B1 (ko) * | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
AU2009210654A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and bevacizumab to treat colorectal cancer |
EP2242773B1 (en) | 2008-02-11 | 2017-06-14 | Cure Tech Ltd. | Monoclonal antibodies for tumor treatment |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
EP2280997A2 (en) * | 2008-04-18 | 2011-02-09 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
EP2350129B1 (en) | 2008-08-25 | 2015-06-10 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
AU2009288289B2 (en) | 2008-08-25 | 2012-11-08 | Amplimmune, Inc. | PD-1 antagonists and methods of use thereof |
SI2342226T1 (sl) * | 2008-09-26 | 2016-11-30 | Dana-Farber Cancer Institute Inc. | Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe |
KR101050829B1 (ko) * | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제 |
EP3929216A1 (en) * | 2008-12-09 | 2021-12-29 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
SG175289A1 (en) * | 2009-04-20 | 2011-11-28 | Genentech Inc | Adjuvant cancer therapy |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
PT2785375T (pt) | 2011-11-28 | 2020-10-29 | Merck Patent Gmbh | Anticorpos anti-pd-l1 e usos destes |
CA2934028A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
CA2988420A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
-
2013
- 2013-05-30 SG SG10201603055WA patent/SG10201603055WA/en unknown
- 2013-05-30 MX MX2014014485A patent/MX363872B/es active IP Right Grant
- 2013-05-30 PL PL13729174T patent/PL2855528T3/pl unknown
- 2013-05-30 CN CN201380023297.7A patent/CN104271601B/zh active Active
- 2013-05-30 KR KR1020207018423A patent/KR20200079568A/ko not_active Application Discontinuation
- 2013-05-30 EP EP19169142.7A patent/EP3556776A1/en not_active Withdrawn
- 2013-05-30 RU RU2014147867A patent/RU2689760C2/ru active
- 2013-05-30 MY MYPI2014003317A patent/MY186099A/en unknown
- 2013-05-30 SG SG11201407859YA patent/SG11201407859YA/en unknown
- 2013-05-30 ES ES13729174T patent/ES2742379T3/es active Active
- 2013-05-30 AR ARP130101910 patent/AR091220A1/es unknown
- 2013-05-30 WO PCT/US2013/043452 patent/WO2013181452A1/en active Application Filing
- 2013-05-30 KR KR1020147036543A patent/KR102129636B1/ko active IP Right Grant
- 2013-05-30 AU AU2013267267A patent/AU2013267267B2/en active Active
- 2013-05-30 CA CA2874144A patent/CA2874144C/en active Active
- 2013-05-30 BR BR112014029887A patent/BR112014029887A8/pt not_active Application Discontinuation
- 2013-05-30 JP JP2015515207A patent/JP6312659B2/ja active Active
- 2013-05-30 EP EP13729174.6A patent/EP2855528B1/en active Active
-
2014
- 2014-11-18 IL IL235779A patent/IL235779B/en active IP Right Grant
- 2014-11-27 MX MX2019003942A patent/MX2019003942A/es unknown
- 2014-12-01 US US14/556,774 patent/US9895441B2/en active Active
- 2014-12-03 ZA ZA2014/08852A patent/ZA201408852B/en unknown
-
2015
- 2015-02-11 HK HK15101499.7A patent/HK1200857A1/xx unknown
-
2018
- 2018-01-09 US US15/866,325 patent/US20180236066A1/en not_active Abandoned
- 2018-01-18 JP JP2018006588A patent/JP2018109002A/ja not_active Withdrawn
- 2018-01-19 AU AU2018200449A patent/AU2018200449B2/en active Active
-
2019
- 2019-10-04 JP JP2019183482A patent/JP2020033355A/ja active Pending
-
2020
- 2020-02-16 IL IL272687A patent/IL272687A/en unknown
- 2020-03-27 AU AU2020202203A patent/AU2020202203A1/en not_active Abandoned
-
2022
- 2022-02-14 US US17/671,306 patent/US20220362378A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272687A (en) | Cancer treatment methods using PD-L1 axis binding antagonists and VEGF antagonists | |
IL283429A (en) | Methods for cancer treatment using PD-1 axis binding antagonists and TIGIT inhibitors | |
IL274059B (en) | Methods for treating cancer using axis 1-pd antagonists and mek inhibitors | |
IL270943A (en) | Biomarkers and methods for the treatment of 1-PD and PD-L1 related conditions | |
IL245857A0 (en) | Methods for the treatment of cancers using pd-1 spindle-binding antagonists and taxanes | |
IL246183A0 (en) | Methods for cancer treatment using pd-1 spindle-binding antagonists and anti-cd20 antibody | |
HUE059632T2 (hu) | T-sejteket aktiváló bispecifikus antigénkötõ molekulák és PD-1 tengelyt célzó antagonisták kombinációs terápiája | |
EP2919759A4 (en) | MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES | |
EP2825693A4 (en) | METHOD AND MATERIALS FOR THE TREATMENT OF CANCER |